Aman's Global Market Intelligence

Executive dashboard

S&P 500 · Thu7,730.99+0.72%

Nasdaq · Thu26,541.35+1.57%

Dow · Thu53,569.44+0.20%

Russell 2000 · Thu3,014.34+0.28%

VIX · Thu14.51low-volatility regime

U.S. futures · 08:21ES −0.08%NQ −0.27% · YM +0.14%

U.S. 2Y / 10Y · 08:304.234% / 4.682%curve +44.8 bp

Dollar index · 08:3199.166+0.01%

WTI Oct / Gold Dec$82.88 / $4,635.90−0.78% / −0.60%

Nikkei / Hang Seng66,438 / 25,608+0.46% / +0.16%

Shanghai3,960.36+0.10%

Europe · Thu closeSTOXX 600 651.85FTSE −0.79% · DAX 26,367

1 · Cash confirmation

NVIDIA delivered the price confirmation

NVDA closed $227.98, +8.74% on 298.9M shares; Nasdaq gained 1.57%. This validates Thursday's conditional AI setup, but a one-day vertical move increases chase and reversal risk. Nasdaq quote · NVIDIA release

2 · Earnings dispersion

Marvell growth did not clear the bar

MRVL closed −1.49% at $241.45, then fell to $222.62 (−7.80%) after hours. Q2 revenue was a record $2.739B (+37% y/y), non-GAAP EPS $0.94, and Q3 revenue guidance $3.150B ±5%; expectation saturation matters. SEC 8-K/exhibit

3 · Macro/geopolitics

Rates and Hormuz cap enthusiasm

The 10Y is 4.682%, NQ futures are −0.27%, and CNBC reports Iran linking Hormuz reopening to an end to regional wars. WTI is down, but headline-driven shipping disruption remains a gap risk. CNBC 10Y · CNBC

Market drivers

Macro, central banks and geopolitics

Breadth lagged tech: Nasdaq +1.57% and S&P +0.72% far outpaced Dow +0.20% and Russell +0.28%. This was an AI/mega-cap impulse, not uniform risk appetite. Nasdaq · Russell
Discount-rate pressure: 10Y 4.682% is roughly 3 bp above Thursday morning's observation; 2Y is 4.234%. High-duration AI, quantum and pre-profit biotech remain sensitive even when earnings are strong. 10Y · 2Y
Fed catalyst: the next scheduled FOMC meeting and projections are Sep. 15–16. Until then, inflation/labor surprises can reprice a still-high curve. Federal Reserve calendar
Geopolitical divergence: WTI −0.78% says immediate disruption is not being priced, while fresh Hormuz rhetoric keeps the tail risk alive. Do not treat a lower oil print as resolution. WTI · CNBC context

Earnings, regulation and rotation

NVIDIA: the +8.74% cash reaction confirms investors accepted fiscal Q2 revenue $96.2B and Q3 guidance $108B ±2%, despite China exclusion and a 74% non-GAAP gross-margin guide. The next question is whether $225–228 can become support. SEC 10-Q
Marvell: data-center revenue grew 46% y/y and management raised fiscal 2027/2028 revenue outlooks, yet the stock fell 7.8% post-market. Strong fundamentals plus a negative reaction is a warning about embedded expectations, margin mix and valuation. SEC exhibit
AI rotation: AVGO +4.49%, VRT +2.07%, while ANET −0.57% and MRVL −1.49%. Power/cooling and custom-silicon exposures diverged; NVIDIA demand does not translate one-for-one into every supplier's stock. VRT · MRVL
Policy: CNBC reports a judge blocked the Pentagon's designation of Anthropic as a supply-chain risk. That reduces one immediate cloud/AI procurement overhang, but litigation and government contracting remain uncertain. CNBC

Theme dashboards

AI · selective

Compute and power lead; networking disperses

Leaders: CRM +22.58%, NVDA +8.74%, AVGO +4.49%, VRT +2.07%. NVIDIA's guide supports compute, networking, power and cooling; the price tape confirms compute enthusiasm.
Laggards: MRVL −1.49% cash and −7.80% post-market; ANET −0.57%. Marvell's strong Q2/Q3 numbers failing the expectation test is the key warning.
Risk: valuation, 4.68% 10Y, export policy, customer concentration, margin mix, power/interconnect constraints and capex expectation saturation.

Quantum · speculative rebound

High-beta bounce, not commercial de-risking

Leaders: IONQ +6.07%, QUBT +3.59%, RGTI +3.14%, QBTS +2.23%; all beat Nasdaq except QBTS.
Evidence limit: no new primary commercial milestone was identified in today's successful feeds. QBTS still faces the Sep. 2 acting-CFO transition disclosed in its Aug. 25 8-K. SEC
Risk: cash burn, dilution, architecture/commercialization uncertainty, extreme valuation and squeeze risk. No borrow availability or fee is asserted.

Peptide biotech · weak

Large and small names both lag

Thursday: LLY −1.12%, NVO −1.97%, VKTX −1.51% while Nasdaq rose 1.57%; no relative leader emerged.
Retatrutide registry: TRIUMPH-2 is a completed, randomized, double-blind Phase 3 study with 1,152 actual participants. Primary outcomes include percent body-weight change and AHI change in a subset at week 80; no results/statistics are posted. NCT05929079
Risk: efficacy, GI/other safety, discontinuation, manufacturing, reimbursement, label scope and competition. VKTX remains small-cap and binary/financing exposed.

Ranked ideas — conditional; fewer is better

1Conditional bullish

VRT · Vertiv (NYSE)

Risk class: large-cap/high-beta AI power and cooling · Classification: relative-strength continuation only on confirmation · Applicable horizon: day trade and 1–4 week swing; 3–12+ months only with backlog, margin and FCF delivery. Direction uncertain.

Thesis/catalyst: VRT closed $269.28 (+2.07%) after reclaiming $260 Wednesday, while NVIDIA validated AI-factory demand. It is the cleanest two-day relative-strength sequence in the infrastructure basket.

Evidence / counterargument: Nasdaq verifies price and 4.61M volume; NVIDIA's outlook supports ecosystem demand. Counter: demand does not map one-for-one to VRT orders, the move may be extended, and Marvell shows expectations can overwhelm fundamentals.

Entry/confirmation: controlled hold above $267–269 with strength versus NQ; better entry is a base, not a vertical gap. Invalidation/downside: close below $263, then $255; gaps can exceed levels. Key risks: rates, capex timing, execution, competition and valuation. Nasdaq

Thesis Confidence 76

Risk 83

Opportunity 69

2Conditional bullish

ANET · Arista Networks (NYSE)

Risk class: large-cap, high-valuation AI networking · Classification: consolidation-break long, not immediate chase · Applicable horizon: day trade and 1–4 week swing; 3–12+ months on revenue/FCF execution. Direction uncertain.

Thesis/catalyst: ANET held $201.09 after Wednesday's +5.92% breakout. A shallow −0.57% pullback while NVDA confirmed demand is constructive if $200 holds.

Evidence / counterargument: Nasdaq verifies the Aug. 27 close and 4.70M volume. Counter: it did not participate in Thursday's rally, customer concentration and competition matter, and a break below the breakout would imply distribution.

Entry/confirmation: reclaim $202.25 and then clear Thursday's range with positive networking breadth. Invalidation/downside: close below $197; below $193.15 breaks the prior trigger. Risks: rates, valuation, concentration, execution. Nasdaq

Thesis Confidence 72

Risk 82

Opportunity 64

1Avoid / bearish failed reclaim

MRVL · Marvell Technology (Nasdaq)

Risk class: large-cap/high-beta post-earnings semiconductor · Classification: avoid dip-buying; bearish only on failed rebound · Applicable horizon: day trade after price discovery and 1–4 week observe; 3–12+ months requires valuation/cash-flow work. Direction uncertain. Short risk is unlimited.

Thesis/catalyst: MRVL fell from $241.45 to $222.62 after hours (−7.80%) despite record $2.739B revenue and $3.150B ±5% Q3 guidance. Negative reaction to strong data is an expectations warning.

Evidence / counterargument: SEC verifies revenue, EPS, guidance and 46% data-center growth; CNBC direct quote verifies the post-market print. Counter: raised multi-year outlook, robust AI bookings and a reclaim can trigger a sharp reversal.

Entry/confirmation: no blind short at the open; bearish confirmation is failure below $225 after a bounce or break below $220. Invalidation/downside: bearish view invalid on a sustained reclaim of $230, then $241.45. Risks: gap reversal, squeeze, AI demand, volatility. Borrow/fees unknown. SEC · CNBC

Thesis Confidence 88

Risk 96

Opportunity 61

2Avoid / no relative strength

NVO · Novo Nordisk ADR (NYSE)

Risk class: large-cap pharmaceutical, clinical/regulatory and FX exposed · Classification: avoid until reversal; not an outright short · Applicable horizon: 1–4 week swing watch and 3–12+ month only after fundamental/technical stabilization. Direction uncertain.

Thesis/catalyst: NVO fell 1.97% to $46.26 after already violating the prior $47.50 bullish invalidation. It underperformed a +1.57% Nasdaq and lacks a verified near-term positive catalyst in today's retrievals.

Evidence / counterargument: Nasdaq verifies the decline on 13.0M shares. Counter: obesity-market growth, pipeline progress, pricing or manufacturing improvements could trigger rerating; this is avoidance, not a claim the franchise is broken.

Entry/confirmation: no long until reclaim of $47.20–47.50 and relative strength versus healthcare. Invalidation/downside: avoidance view expires above $48; further weakness below $46 worsens structure. Risks: clinical data, safety, competition, reimbursement, manufacturing, FX. Nasdaq

Thesis Confidence 72

Risk 70

Opportunity 45

No third bullish or bearish idea: NQ futures are fading, long yields are elevated and Thursday's sharp moves create poor entry asymmetry. Quotas are not targets.

Watchlist — maximum five

Ticker / risk class	Classification & horizon	Thesis / catalyst / counterargument	Confirmation / invalidation / key risks	C / R / O
Watch NVDA Nasdaq · mega-cap, post-earnings/high expectations	Gap digestion; day/swing after base, 3–12 months on growth/margins.	+8.74% to $227.98 confirms the Q2/Q3 story. Counter: move is extended and post-market slipped 0.80% to $226.15.	Hold $225 then clear $228; below $220 weakens. Valuation, China/export rules, margin and gap risk.	92 / 91 / 65
Watch AVGO Nasdaq · mega-cap custom silicon/networking	Sep. 2 earnings; day/swing after results, long term on FCF/guidance.	+4.49% to $371.54; next major AI confirmation point. Counter: event expectations and customer concentration.	No pre-event chase; $371–372 hold or post-result base. Below $360 weakens. Leverage, rates, event gap.	75 / 94 / 63
Watch CRM NYSE · large-cap enterprise cloud	Post-earnings gap digestion; day/swing only after base.	+22.58% to $252.05 on 53.6M shares is exceptional. Counter: vertical gaps often mean-revert and investment gains are not recurring operating revenue.	Hold $250 and form a base; below $245 warns. Execution, valuation, gap reversal, AI monetization quality.	76 / 94 / 58
Watch IONQ / RGTI / QBTS NYSE/Nasdaq · speculative quantum	Momentum watch, not core buy; day only, 1–4 week observe.	+6.07%/+3.14%/+2.23% rebound. Counter: no verified new commercial de-risking; Wednesday's selloff showed fragility.	Require follow-through above $42.46/$16.44/$17.90. New lows invalidate. Cash burn, dilution, commercialization, squeeze.	66 / 98 / 44
Watch VKTX Nasdaq · small-cap, binary peptide biotech	Clinical/financing watch; swing only on confirmed news; 3–12 months on data.	−1.51% to $33.86, no relative strength. Counter: positive trial/manufacturing evidence could reprice sharply.	Reclaim $34.38/$35; below $33 weakens. Trial endpoints/statistics/safety unknown until disclosed; runway, dilution, competition.	62 / 93 / 49

C / R / O = Thesis Confidence / Risk / Opportunity. Confidence measures evidence quality, not outcome probability.

Changes versus the 2026-08-27 report

Regime is downgraded from conditional risk-on to neutral/selective: Thursday cash confirmed the NVIDIA impulse, but Friday NQ futures −0.27%, 10Y 4.682%, MRVL's negative reaction and Hormuz risk reduce near-term asymmetry.
NVDA price discovery is complete: it closed +8.74% at $227.98, validating the prior no-chase setup's fundamental read-through. It remains a watch rather than a ranked long because the move is now extended.
VRT becomes the top conditional long: it advanced another 2.07% to $269.28 and held the prior $260 trigger; invalidation tightens from $255 to $263 tactically.
ANET holds but does not lead: −0.57% at $201.09 preserves the breakout, yet underperformance versus Nasdaq requires a reclaim of $202.25 before entry.
MRVL changes from pre-earnings watch to top avoid/failed-reclaim candidate: record growth and strong guidance did not prevent a 7.80% post-market decline.
Quantum caution is not invalidated: the basket rebounded 2.23%–6.07%, but no primary commercial milestone was identified; QBTS bearish entry never triggered because it reclaimed $17.90.

Important catalysts: next 7–30 days

Aug. 28 · U.S. open — MRVL/NVDA post-earnings digestion
MRVL's −7.80% post-market print and NVDA's +8.74% cash surge can drive networking, custom silicon, power and cooling. Premarket stock price discovery had not begun at the nominal cutoff. MRVL · NVDA

Sep. 2 · after U.S. close — Broadcom earnings / D-Wave CFO transition
Nasdaq lists AVGO with eight EPS estimates averaging $2.83; this is vendor consensus, not guidance. QBTS's acting-CFO transition becomes effective. Nasdaq calendar · QBTS SEC

Sep. 3 · 14:30 CEST — U.S. trade balance
BEA schedules July U.S. international trade in goods and services. Trade/tariff effects can move dollar, rates and cyclicals. BEA schedule

Sep. 15–16 · FOMC + projections
Statement, SEP and press conference are the major 30-day duration catalyst for AI, quantum and biotech. Federal Reserve

Pipeline watch · date unconfirmed
TRIUMPH-2 is completed, but ClinicalTrials.gov still posts no results. No Lilly readout date or statistics are assumed. Registry

Bottom line by horizon

Day trade

Bias: neutral until price discovery. Prefer VRT only on a $267–269 hold; ANET only above $202.25. Do not chase NVDA, CRM or short MRVL's first print.

Biggest risk: opening-gap reversal or Hormuz headline. Invalidation: risk-on improves if NQ recovers overnight losses and semis broaden; worsens if MRVL drags networking and NQ loses Thursday's impulse.

1–4 week swing

Bias: selective AI infrastructure after consolidation, not broad theme chasing. VRT above $263 and ANET above $197 are the preferred conditional structures.

Biggest risk: 4.68%+ 10Y and expectation saturation. Invalidation: S&P closes back below 7,675 and leaders lose post-earnings breakout support.

3–12+ month investment

Bias: favor profitable AI infrastructure with verified growth/FCF; demand commercial proof in quantum and complete clinical/regulatory evidence in peptide biotech.

Biggest risk: peak capex, margin compression, policy or geopolitical shock. Invalidation: sustained order/growth deterioration, rising dilution, failed endpoints or worsening cash runway.

Data quality & methodology

Timestamp/session: generated Friday 08:35:40 CEST. CNBC direct exchange quote API was observed 08:21–08:31 CEST. U.S. cash indices and Nasdaq stock data are Aug. 27 closes; futures/rates/FX/commodities are overnight; MRVL is a Thursday post-market indication. Asian quotes were late-session. Europe and Friday Nasdaq premarket had not opened at the nominal cutoff.
Successful live retrievals: CNBC direct market/stock APIs and two RSS feeds; Nasdaq quote, extended-trading and earnings APIs; SEC company-ticker, submissions, filing index/full submission; Marvell IR quarterly page; ClinicalTrials.gov API; Fed calendar; BEA schedule. More than five meaningful calls covered market data, current news and primary sources.
Cross-check: Nasdaq independently timestamps Aug. 27 stock closes and reports NVDA 298.9M, VRT 4.61M and MRVL 41.0M consolidated volume. SEC's Marvell exhibit verifies $2.739B Q2 revenue, $0.94 non-GAAP EPS, $3.150B ±5% Q3 revenue guide and 46% data-center growth. The company IR page links the same Aug. 27 fiscal-Q2 materials.
Source limitations: CNBC's bulk stock cache mislabels regular-session dates as Aug. 26 while its embedded extended-market objects and Nasdaq show Aug. 27; Nasdaq is authoritative for stock close dates. Nasdaq extended-trading endpoints returned empty objects, so CNBC's direct quote is used for MRVL's after-hours print. Marvell RSS returned HTML instead of XML, but IR HTML and SEC succeeded. Fed RSS parsed without items in the attempted namespace, so the official calendar page is used.
Blocked alternatives: Yahoo was not retried because Nasdaq/CNBC cross-checks succeeded; generic web search/extraction returned payment-required/insufficient-credit errors; direct curl to BEA/Fed/Marvell succeeded instead. The BLS September page returned a 1.3KB block page, so no BLS date is asserted. Current data are not declared unavailable where alternatives worked.
Scoring: Confidence is evidence quality, never guaranteed probability. Risk rises with event gaps, valuation, liquidity, leverage, dilution, management transition and binary exposure. Opportunity balances asymmetry, evidence and timing. Levels are paper-tracking references, not orders.

Sources

Research disclaimer: Research and paper-tracking only—not individualized, guaranteed, fiduciary, legal or medical advice. Initial two weeks are paper-tracking. Prices can gap beyond invalidation levels; shorts can lose more than invested. Verify quotes, liquidity, taxes and suitability independently.